Core Insights - Seres Therapeutics, Inc. is a clinical-stage company focused on live biotherapeutics aimed at improving patient outcomes in medically vulnerable populations [2] - The company will present an overview at the H.C. Wainwright Global Investment Conference on September 8, 2025 [1] Company Overview - Seres Therapeutics is known for developing VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024 [2] - The company is currently developing SER-155, which has received Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing infection risk and graft-versus-host disease in the same patient group [2] - SER-155 has shown a significant reduction in bloodstream infections and related complications compared to placebo in a Phase 1b clinical study [2] Pipeline and Future Plans - The company’s pipeline includes SER-155 and other cultivated live biotherapeutic candidates targeting various disease-relevant pathways [2] - In addition to allo-HSCT, SER-155 and other candidates will be evaluated in other medically vulnerable populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, and patients in intensive care and long-term acute care facilities [2]

Core Viewpoint - DBV Technologies will participate in the EAACI Congress 2025, presenting new data on its VIASKIN® peanut patch and hosting a symposium focused on peanut allergy research [1][3][4] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions, utilizing its proprietary VIASKIN® patch technology [7][8] - The company aims to address food allergies through epicutaneous immunotherapy (EPIT™), which introduces microgram amounts of allergens to the immune system via the skin [7] Upcoming Presentations - At the EAACI Congress, DBV will present data from the EPITOPE open-label extension trial, highlighting reduced rates of reactions from accidental peanut consumption with the VIASKIN® peanut patch [2][4] - The APTITUDE study results will also be shared, evaluating the sensitivity, specificity, and safety of the VIASKIN® patch for diagnosing non-IgE mediated cow's milk allergy in infants [2][4] Symposium Details - The symposium titled "Peanut Allergy: Recent Research Highlights" will be co-chaired by Prof Gideon Lack and Prof Alexandra Santos, featuring discussions on the clinical relationship between allergists and food-allergic patients [3][5] - Presentations will include insights on epicutaneous immunotherapy and new clinical data related to peanut allergy [6][7] Clinical Data Highlights - Year 2 data from the EPITOPE trial will demonstrate real-world protective effects of the VIASKIN® peanut patch in peanut-allergic toddlers, showing further reductions in accidental peanut consumption-related reactions [4][7] - The APTITUDE study, despite early termination due to enrollment challenges, is viewed as a positive step in demonstrating the potential of the VIASKIN® patch in food allergy management [4][7]

Core Insights - The FDA has provided constructive feedback on Seres Therapeutics' SER-155 development plans, supporting a Phase 2 study with a primary efficacy endpoint focused on reducing bloodstream infections (BSIs) post-allo-HSCT [1][2][4] - Seres Therapeutics plans to submit a proposed protocol for the next SER-155 study to the FDA in Q2 2025, incorporating the agency's feedback [1][2] - SER-155 has shown a 77% relative risk reduction in BSIs in a Phase 1b study, along with reduced systemic antibiotic exposure and lower incidence of febrile neutropenia [2][4] Company Overview - Seres Therapeutics, Inc. is a clinical-stage company focused on live biotherapeutics aimed at improving outcomes for medically vulnerable populations [5] - The company has received Breakthrough Therapy designation for SER-155, targeting the reduction of BSIs in allo-HSCT patients, and Fast Track designation for reducing infection risk and graft-versus-host disease [5][4] - SER-155 is designed to decolonize gastrointestinal pathogens and improve immune tolerance in patients undergoing allo-HSCT for hematological malignancies [3][5] Future Development Plans - The next study design for SER-155 may retain elements from the previous Phase 1b trial, which demonstrated significant clinical benefits [2][4] - The company is actively seeking partnerships to support the further development of SER-155 in allo-HSCT [2]